Molecular imaging of tumor angiogenesis
Molecular imaging of tumor angiogenesis
复制标题
DOI：
10.1002/jcb.10426
复制
发表时间：
2002-01-01
影响因子：
4
通讯作者：
Libutti, SK
中科院分区：
文献类型：
--
作者：
Costouros, NG;Diehn, FE;Libutti, SK
血管生成作为癌症治疗的一个重要靶点的出现，导致旨在理解肿瘤血管系统的发育、维持和破坏机制的研究增多。同时，分子成像技术已经得到发展，并且由于其能够无创地监测体内分子事件，正被纳入生物医学研究的组成部分。随着众多抗血管生成药物在临床试验中得到评估，对用于监测血管生成的分子成像模式的调整和验证正在积极进行。由于血管表型的多效性，在血管生成研究中选择合适的分子靶点的重要性变得日益复杂。此外，由于肿瘤组织中内皮细胞相对较少以及检测分子事件本身存在困难，血管系统的分子成像需要在提高灵敏度方面不断改进。虽然已经发表了一些为血管生成成像奠定基础的研究，但还有很多工作要做。各种肿瘤模型和转基因小鼠为开发用于理解血管生成的分子成像技术提供了极好的资源。这项研究在抗血管生成药物的临床前测试中评估机制和疗效方面可能发挥特别关键的作用。然而，由于实际限制，针对血管生成的分子成像的应用可能不会超出高度专业化的临床试验范围。也就是说，在功能层面评估血管生成的成像模式可能更合适。尽管未来存在技术挑战，分子成像将成为评估肿瘤血管生成的重要研究和临床工具。
The emergence of angiogenesis as an important target for cancer therapy has led to Increased research aimed at understanding the mechanisms underlying the development, maintenance, and destruction of tumor vasculature. Concurrently, molecular imaging technologies have been developed and arc, being incorporated as integral components of biomedical research due to their ability to noninvasively monitor in vivo molecular events. With the evaluation of numerous anti-angiogenic agents in clinical trials, the adaptation and validation or molecular Imaging modalities for monitoring angiogenesis is actively being pursued. The importance of selecting appropriate molecular targets in the study of angiogenesis has become increasingly complex due to the pleiotropy of vascular phenotypes. Furthermore, due to both the relatively low abundance of endothelial cells in tumor tissue and the inherent difficulties of detecting molecular events, molecular imaging of vasculature necessitates continued improvements in achieving higher sensitivity. While several studies have been published that set the groundwork for imaging angiogenesis, much has yet to be accomplished. Various tumor models and transgenic mice provide an excellent resource for developing molecular imaging technologies for the understanding of angiogenesis, This research may play a particularly crucial role in evaluating mechanism and efficacy during pre-clinical testing of anti-angiogenic drugs. Due to practical limitations, however, the implementation of angiogenesis-directed molecular imaging may not extend beyond highly specialized clinical trials. That is, imaging modalities that evaluate angiogenesis at a functional level may prove more appropriate, Despite future technical challenges, molecular imaging will become an important research and clinical tool in evaluating tumor angiogenesis.